N-benzylundecan-1-amine

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-benzylundecan-1-amine
• 化学式: C₁₈H₃₁N
• 分子量: 261.451
• InChiKey: VCFMSZPEUJDWDN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.3
• 重原子数：
  19
• 可旋转键数：
  12
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  12
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  十一烷醇 在 sodium hydroxide 作用下， 以 四氢呋喃 、 乙醇 为溶剂， 反应 32.25h， 生成 N-benzylundecan-1-amine
  参考文献：
  名称：

  [EN] PYRROLOPYRIMIDINE DERIVATIVES USEFUL AS INHIBITORS OF INFLUENZA VIRUS REPLICATION
  [FR] DÉRIVÉS DE PYRROLOPYRIMIDINE UTILES EN TANT QU'INHIBITEURS DE LA RÉPLICATION DU VIRUS DE LA GRIPPE

  摘要：

  抑制生物样本或患者中流感病毒复制的方法，减少生物样本或患者中流感病毒的数量，以及治疗患者的流感，包括向所述生物样本或患者投予任何一种代表为Formula l-lll的化合物或其药学上可接受的盐的安全有效量。一种药物组合物包括这种化合物或其药学上可接受的盐的安全有效量，以及药学上可接受的载体、辅料或溶剂。

  公开号：

  WO2018200425A1

文献信息

• [EN] PYRROLOPYRIMIDINE DERIVATIVES USEFUL AS INHIBITORS OF INFLUENZA VIRUS REPLICATION<br/>[FR] DÉRIVÉS DE PYRROLOPYRIMIDINE UTILES EN TANT QU'INHIBITEURS DE LA RÉPLICATION DU VIRUS DE LA GRIPPE
  申请人：COCRYSTAL PHARMA INC

  公开号：WO2018200425A1

  公开（公告）日：2018-11-01

  Methods of inhibiting the replication of influenza viruses in a biological sample or patient, of reducing the amount of influenza viruses in a biological sample or patient, and of treating influenza in a patient, comprises administering to said biological sample or patient a safe and effective amount of a compound represented by any of Formulas l-lll, or a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprises a safe and effective amount of such a compound or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, adjuvant or vehicle.

  抑制生物样本或患者中流感病毒复制的方法，减少生物样本或患者中流感病毒的数量，以及治疗患者的流感，包括向所述生物样本或患者投予任何一种代表为Formula l-lll的化合物或其药学上可接受的盐的安全有效量。一种药物组合物包括这种化合物或其药学上可接受的盐的安全有效量，以及药学上可接受的载体、辅料或溶剂。
• Materials for hydrophilic interaction chromatography and processes for preparation and use thereof for analysis of glycoproteins and glycopeptides
  申请人：Waters Technologies Corporation

  公开号：US10119944B2

  公开（公告）日：2018-11-06

  The invention relates to poly-amide bonded hydrophilic interaction chromatography (HILIC) stationary phases and novel HILIC methods for use in the characterization of large biological molecules modified with polar groups, known to those skilled in the art as glycans. The invention particularly provides novel, poly-amide bonded materials designed for efficient separation of large biomolecules, e.g. materials having a large percentage of larger pores (i.e. wide pores). Furthermore, the invention advantageously provides novel HILIC methods that can be used in combination with the stationary phase materials described herein to effectively separate protein and peptide glycoforms by eliminating previously unsolved problems, such as on-column aggregation of protein samples, low sensitivity of chromatographic detection of the glycan moieties, and low resolution of peaks due to restricted pore diffusion and long intra/inter-particle diffusion distances.

  本发明涉及聚酰胺键合亲水相互作用色谱（HILIC）固定相和新型 HILIC 方法，用于表征用极性基团修饰的大生物分子，本领域技术人员已知这些极性基团为聚糖。本发明特别提供了设计用于高效分离大型生物分子的新型聚酰胺键合材料，例如具有较大孔隙比例的材料（即宽孔）。此外，本发明还有利地提供了新型 HILIC 方法，该方法可与本文所述的固定相材料结合使用，通过消除以前未解决的问题（如蛋白质样品的柱上聚集、糖分子的色谱检测灵敏度低以及由于孔扩散受限和颗粒内/颗粒间扩散距离长而导致的峰分辨率低）来有效分离蛋白质和肽的糖型。
• Porous materials for solid phase extraction and chromatography and processes for preparation and use thereof
  申请人：Brousmiche Darryl W.

  公开号：US10258979B2

  公开（公告）日：2019-04-16

  The invention provides novel porous materials that are useful in chromatographic processes, e.g., solid phase extraction, and that provide a number of advantages. Such advantages include superior wetting characteristics, selective capture of analytes of interest, and non-retention of interfering analytes. In certain aspects, the materials feature at least one hydrophobic component, at least one hydrophilic component and a average pore diameter of about 100 Åto about 1000 Å. In certain embodiments the materials also exhibit a nitrogen content from about 1% N to about 20% N. In certain embodiments, the materials also exhibit more than 10% of the BJH surface area of the porous material is contributed by pores that have a diameter greater than or equal to 200 Å. The invention advantageously provides novel porous materials having a large percentage of larger pores (i.e. wide pores). The invention advantageously provides novel porous materials that overcome the problems of SPE of biological samples.

  本发明提供的新型多孔材料可用于色谱过程，如固相萃取，并具有许多优点。这些优点包括优异的润湿特性、选择性捕获感兴趣的分析物以及不截留干扰分析物。在某些方面，这些材料具有至少一种疏水成分、至少一种亲水成分和约 100 Å 至约 1000 Å 的平均孔径。在某些实施例中，材料的氮含量从约 1% N 到约 20% N。在某些实施例中，材料还显示多孔材料 10% 以上的 BJH 表面积是由直径大于或等于 200 Å 的孔贡献的。本发明提供的新型多孔材料具有很大比例的较大孔隙（即宽孔隙）。本发明提供的新型多孔材料克服了生物样品 SPE 的问题。
• Pyrrolopyrimidine derivatives useful as inhibitors of influenza virus replication
  申请人：COCRYSTAL PHARMA, INC.

  公开号：US11014941B2

  公开（公告）日：2021-05-25

  Methods of inhibiting the replication of influenza viruses in a biological sample or patient, of reducing the amount of influenza viruses in a biological sample or patient, and of treating influenza in a patient, comprises administering to said biological sample or patient a safe and effective amount of a compound represented by any of Formulas I-III, or a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprises a safe and effective amount of such a compound or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, adjuvant or vehicle.

  抑制生物样本或患者体内流感病毒复制、减少生物样本或患者体内流感病毒数量以及治疗患者流感的方法，包括向所述生物样本或患者施用安全有效量的由式I-III中任一项代表的化合物或其药学上可接受的盐。药物组合物包括安全有效量的此类化合物或其药学上可接受的盐，以及药学上可接受的载体、佐剂或载体。
• MONOLITHIC ELECTROKINETIC PUMP FABRICATION
  申请人：Waters Technologies Corporation

  公开号：EP2079665A2

  公开（公告）日：2009-07-22